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Abstract: Pancreatic cancer has been classified as a cancer of unmet need. After diagnosis the patient
prognosis is dismal with few surviving over 5 years. Treatment regimes are highly patient variable and
often the patients are too sick to undergo surgical resection or chemotherapy. These chemotherapies
are not effective often because patients are diagnosed at late stages and tumour metastasis has
occurred. Nanotechnology can be used in order to formulate potent anticancer agents to improve
their physicochemical properties such as poor aqueous solubility or prolong circulation times after
administration resulting in improved efficacy. Studies have reported the use of nanotechnologies
to improve the efficacy of gemcitabine (the current first line treatment) as well as investigating the
potential of using other drug molecules which have previously shown promise but were unable to
be utilised due to the inability to administer through appropriate routes—often related to solubility.
Of the nanotechnologies reported, many can offer site specific targeting to the site of action as well
as a plethora of other multifunctional properties such as image guidance and controlled release.
This review focuses on the use of the major nanotechnologies both under pre-clinical development
and those which have recently been approved for use in pancreatic cancer therapy.
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1. Introduction
Pancreatic cancer (PC) is the 4th common cause of cancer related mortality in the western world
and is predicted to become the 2nd leading cause by 2030 [1]. Despite significant developments in
the treatment of other cancer types, the 5-year survival rate for PC (approximately 5%) remains the
same. Pancreatic adenocarcinoma (PDAC) makes up >90% of PCs [2] and is the most demanding
PC to treat [3]. PDAC is the only gastrointestinal (GI) malignancy with the lowest survival and with
the lowest quality prognosis [1]. PC is usually diagnosed at a later stage and is strongly resistant to
chemo- and radiation therapy [4] due to lack of distinctive side effects. The mechanisms concealed in
PC growth and progression are yet to be thoroughly clarified, obstructing the progress of treatment
schemes for disease management. Major challenges of PC today are potential metastatic spread,
high local recurrence and chemo-resistance induced by cancer cell stems [5]. Among the current
crucial issues with PC today is that current CT and MRI imaging techniques are unable to precisely
detect and visualise the cancer stage to obtain a measure of the extent of cancer burden, which would
allow selecting a suitable treatment approach based on the cancer stage [6]. The death rate of patients
suffering from PC is predicted to increase by a further 28% by 2026. 80% of the patients diagnosed
with PC are predicted to die within 12 months of diagnosis while as little as 3% will live for 5 years [7].
For PC patients, the majority of the treatments currently accessible are palliative [8]. Gemcitabine
(Figure 1A) is currently the first line treatment used for PC in the UK. Gemcitabine is a pro drug,
which is a drug that is administered in an inactive form and phosphorylated into its clinically active
form gemcitabine triphosphate within cells after cellular uptake [9,10]. This active form inhibits
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DNA elongation by replacing the nucleoside cytidine leading to cell death [11]. Gemcitabine therapy
has been the primary regimen for metastatic or un-resectable locally advanced PC since 1997 [12].
Gemcitabine only takes effect in 23.8% of PC cases [13] believed to be the result of the dense stroma
encasing the tumour and preventing drug penetration [14]. Without the prevalence of obvious
biomarkers, 80–90% of PDAC occurrences undergo late diagnosis and hence surgical resection will
no longer be successful. For the remaining (10–20%) for which it is possible, the patients have a high
incidence of death due to recurrent or metastatic disease [15]. PDAC treatment has also failed due to
chemo- and radiation resistance. A neoadjuvant therapy followed by surgical resection is a possible
solution for tumour resection [16]. Precise chemotherapeutic agents such as gemcitabine can generate
significant sensitisation in cancer cells to radiation making the gemcitabine-radiation combination
the current best neo-adjuvant treatment [17–19]. However, few PDAC patients benefit from the
gemcitabine chemo-sensitising benefits and there are no means of predicting which case will improve
from combined treatment [16,20].
Examples of other drugs which have been used to treat PC include: 5-fluorouracil (5-Fu),
cisplatin and capecitabine. These drugs all inhibit tumour growth by interacting with the processes
involved in the synthesis of new proteins vital for cell proliferation. They also inhibit cell growth
by also inhibiting DNA replication or causing enough stress to the cells leading to apoptosis [21].
Prior to the use of gemcitabine, 5-Fu (Figure 1B) was the first line drug for treating PC. 5-Fu is
a thymidylate synthase inhibitor. This enzyme is responsible for the synthesis of thymidine which
is a nucleoside required for DNA replication. After 5-Fu is administered, it is quickly metabolised
to 5-fluorodeoxyuridine 5′-monophosphate (FduMP) which binds to thymidine synthase blocking
its ability to methylate uracil. Uracil forms base pairs with adenine during DNA transcription. It is
methylated to form thymine which is required for DNA replication. Without the ability to undergo
DNA replication, the cell become starved of thymidine after multiple divisions [22]. 5-Fu can also be
triphosphorylated and become incorporated into RNA in the place of uracil blocking DNA transcription
which ultimately stops the growth of cancerous cells. Gemcitabine replaced 5-Fu because it displayed
fewer and less serious side effects as well as a greater therapeutic effect [12]. Even with the increased
survival rate with gemcitabine the prognosis for PC is still abysmal and urgent improvements and
novel strategies in PC chemotherapeutics are needed.
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Figure 1. Chemical structure of (A) gemcitabine and (B) 5-fluorouracil.
Therefore, more effective strategies are required in order to fulfil the immediate need for
more effective PC therapies. One rapidly emerging field in biomedicine is the development of
nanotechnologies for drug delivery, image guidance and controlled release, which have shown huge
potential for cancer therapy.
2. Nanotechnologies in Cancer
A vast array of research has been carried out using the principles of nanotechnology for
therapeutic drug delivery. Each system has characteristics unique to itself, but in large, for cancer
therapy the ultimate goal is to achieve enhanced drug absorption and permeability in addition to site
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specificity and control over drug release rate [23]. The use of nanotechnologies as drug chaperones
has numerous advantages over traditional excipient technologies such as surfactants and emulsions.
Nanoparticle systems can ‘escort’ drug molecules to the planned destination, avoiding the body’s
natural barriers, hence preventing early drug degradation or metabolism. The size of NPs (1–100 nm)
allows them to interact with biological molecules both within cells and extracellularly which is highly
advantageous for cancer diagnosis [6,24] and therapy [6]. Nanocarriers are straightforward and
inexpensive to synthesise and can easily be customised or tailored for the application. This may
include incorporation of a specific functional group to aid in targeting, or features such as fluorescence
or imaging capability in order to track their journey after administration through to the cellular
level [25].
Nanoparticles are capable of being (a) passively targeted to tumour vasculature through enhanced
permeability and retention effect (EPR) [26] or (b) actively aimed at specific targets after functionalising
with site-specific ligands [27]. Previous research has shown that binding nanoparticles with cytotoxic
agents can enhance tumour penetration and caused more successful treatments [28–30].
Embodying nanoparticle drug carriers with chemotherapeutic drugs has many advantages:
Firstly, the circulation time of the drug increases significantly as drugs are loaded onto or into
nanoparticles which can avoid them being quickly eradicated by liver and kidneys. Next, the size of
the particles results in a passive targeting known as EPR. This phenomenon is caused when the rapidly
forming tumour vasculature does not form properly which results in tiny pores into which nano-sized
preparations can become accumulated. Due to the extremely poor lymphatic drainage in these areas
the nanoparticles are unlikely to leak back out into the circulation and hence higher drug concentration
is achieved at the tumour area. Finally, toxic side effects of adjuvants are prevented by avoiding the
use of adjuvants completely as the often ‘difficult’ lipophilic drugs can easily be incorporated into or
onto the nanoparticle system.
Another possibility for nanotechnology in site specific drug delivery is to exploit active targeting
mechanisms. Here, specific ligands are attached onto the surface of the nanotechnologies such as
peptides, aptamers or antibodies. Addition of these specific ligands will result in the preferential
binding onto receptors on the targeted cells, hence they act as recognition moieties. This results in
highly site-specific targeting, ensuring the nano-formulation reaches its targeted sites and evades other
unwanted cells, resulting in more efficient treatment.
Numerous studies have been carried out using a wide range of nanotechnologies for treatment of
numerous cancers including breast [31,32], ovarian [33,34], colorectal [35,36], prostate cancer [37,38] etc.
The use of nanotechnologies for the enhanced pre-clinical treatment of PC has also been extensively
reported. In this review, we will outline the varied architectures of nano-systems and describe how they
have been used to improve pre-clinical outcomes when tested in vitro/in vivo against this aggressive
disease. Those which have shown promise as drug carriers have been summarised in Table 1.
Table 1. Nanoparticle based drug delivery systems for PC therapy.
Type of Nano-System Name of Nano-System Drug Formulated Testing Phase
Polymer-drug
conjugate
Poly(ethylene glycol)-P(HEMASN38) SN38 Preclinical: In vivo [39]
Poly (TPGS)-PEG-GEM Gemcitabine Preclinical: In vitro [40]
Methacrylate-based GEM-monomer conjugate 3 Gemcitabine Preclinical: In vitro [41]
Poly(ethylene glycol)-block-poly(2-methyl-2-
carboxyl-propylenecarbonate)-graft-dodecanol-graft-
cationic ligand
Gemcitabine Preclinical: In vivo [42]
Block copolymer
Styrene-maleic acid CDF Preclinical: In vitro [43]
Poly(ethylene glycol)-b-poly(glutamic acid) Oxaliplatin Preclinical: In vivo [44]
Mixed micelles
Poly(vinyl pyrrolidone-b-polycaprolactone)
(PVP-b-PCL) and poly(vinyl
pyrrolidone-b-poly(dioxanone-co-methyl
dioxanone)) (PVP-b-P(DX-co-MeDX)
Gemcitabine, doxorubicin,
doxorubicin hydrochloride,
5-fluorouricil and paclitaxel
Preclinical: In vitro [45]
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Table 1. Cont.
Type of Nano-System Name of Nano-System Drug Formulated Testing Phase
Graft polymer Poly(allylamine)-g-cholesterol BNIPDAoct Preclinical: In vivo [46]
Dendrimer
PAMAM—hyaluronic acid CDF Preclinical: In vitro [47]
Poly(ethylene glycol)—PAMAM—poly(ethylene
glycol)-Flt-2 Gemcitabine Hydrochloride Preclinical: In vivo [48]
Thermo-responsive
polymer Poly(diEGMAco-OEGMA300)-b-PEHMA Squalenoyl-gemcitabine Preclinical: In vitro [49]
pH-responsive
polymer Poly(styrene-alt-maleic anhydride) Curcumin Preclinical: In vitro [50]
Ultrasound-responsive
nano-emulsion PEG-PLLA Paclitaxel Preclinical: In vivo [51]
Albumin
Abraxane® Paclitaxel FDA approved 2013 [52]
Abraxane®/Gemcitabine Paclitaxel & gemcitabine Phase III [53]
Inorganic
nanoparticle
Iron oxide-dextran-DOX Doxorubicin Preclinical: In vitro [54]
Iron oxide-antiCD47-GEM Gemcitabine Preclinical: In vitro [55]
Iron oxide-gold BNIPDSpm Preclinical: In vivo [56]
Iron oxide-gold-GEM Gemcitabine Preclinical: In vivo [57]
3. Physiology of Pancreatic Cancer
PC is caused by the formation of neoplasia within the intraepithelial regions of the
pancreas [58–60]. The pancreas is located within the abdomen surrounded by several other organs,
major blood vessels and tissue types. This allows PC to spread quickly to neighbouring areas [60].
Cancers can spread when a single cancer cell enters the bloodstream. They are quickly swept away
and usually settle when they reach a capillary [61]. Afterwards they pass through the wall of the blood
vessel and attach to other tissues, organs or bone forming secondary cancers. The process of cancer
cells emigrating to new sites is highly unlikely because it is very stressful for the cells which nearly
always perish before completing the journey. However, it only takes one out of the multitude of cancer
cells to survive. PC cells have the advantage of being situated near many blood vessels, multiple organ
and tissue targets as well as the lymphatic system. Therefore even with successful treatment PC still
has the possibility of reoccurring from satellite sites [61,62].
Pancreatic adenocarcinoma is characterised by dense solid tumours. Within the tumour
microenvironment, different cells exist including cancerous cells, non-cancerous fibroblast cells and
extracellular matrix. These solid tumours hinder drug permeation, hence without access to the
cancerous cells themselves, many drug treatments prove non-effective. It has been reported, in the
case of these dense PC tumours, that nanotechnologies do not result in EPR accumulation [63–65].
Additionally, the ability of chemotherapies, even if they do penetrate through the dense tumour stroma
to distinguish between the cancerous and the fibroblast cells is not possible and it is likely that the
potent drugs will be directed into and kill the off-target cells, and hence the PC cells will continue to
proliferate and tumour grow. Therefore, active targeting mechanisms are required in order to direct
the drugs to the appropriate cells within this complex microenvironment.
Potential targets for active transport include adhesion molecules such as integrins [66],
other adhesion molecules [67], antigens [68] and proteases [69] which are reportedly upregulated on
the surface of PC cells. These molecules are expressed by stroma tissues and involved in the process of
attachment of PC cells to the fibrous extracellular matrix. Hence, targeting these sites may disrupt the
microenvironment while directing the drug to the specific cells which require treatment.
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4. Nanotechnologies in Pancreatic Cancer
4.1. Polymer Drug Conjugates
Polymer drug conjugates are composed of drug molecules conjugated onto polymers
(Figure 2), which can be applied in diagnosis and detection of cancer. They are characterised by
a rationally designed covalent chemical bond between a hydrophilic polymeric carrier and bioactive
molecule(s) [70]. Often anticancer therapeutics are highly lipophilic and hence cannot progress
through clinical trial as administration becomes too difficult. However, by conjugating the drug onto
the hydrophilic polymer backbone this results in the formation of core-shell aggregates, whereby the
hydrophobic drug exists inside the lipophilic micellar core. Hence, this improves the aqueous solubility
of the anticancer agent and alters drug pharmacokinetics at the whole organism and even subcellular
level [39,71,72]. It also increases the chances to clearly enhance drug therapeutic effect.
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A recent report showing a good example of this has been described by Wang et al. [39]. Here,
a polymer-drug conjugate was developed between a poly(ethylene glycol) based polymer and
7-ethyl-10-hydroxycamptothecin (SN38): poly(ethylene glycol)-P(HEMASN38). SN38 is the active
metabolite of irinotecan, which has shown promise as an anticancer agent for PC. SN38 cannot be
administered in the free drug form to patients due to its poor solubility in both aqueous solutions
and other pharmaceutically approved solvents [73]. Hence conjugation onto the poly(ethylene glycol)
based polymer acts as a means to improve solubility and hence bioavailability. In addition to the SN38
conjugated onto the system, upon aggregation in aqueous media, vismodegib (GDC-0449) was loaded
into the hydrophobic core, offering a dual therapy approach. GDC-0449 is a known hedgehog inhibitor
for the treatment of basal carcinoma. The complex system demonstrated in vitro that the GDC-0449
reversed fibroblast-induced SN38 resistance and consequently a potent in vivo antitumour effect was
achieved using the polymer-drug conjugate. Hence, the system may be applicable for future therapy
of these solid dense tumours where drug penetration is an issue [39].
Converse to most lipophilic cytotoxics, gemcitabine has a log P of 0.28 and does exhibit
a reasonable degree of water solubility (0.8 mg·mL−1). As gemcitabine is the current first line
therapy (with its associated flaws discussed earlier), the majority of the focus in polymer-drug
conjugate formation for PC has been in the development of gemcitabine conjugated systems in order
to increase drug efficacy [74–78]. Here the rationale for conjugation and micellar delivery is in order to
protect the drug from premature degradation and promote elongation in circulation times, which may
ultimately lead to increased therapeutic effect. Khare et al. reported the conjugation of gemcitabine
onto D-alpha-tocopherol-poly(ethylene glycol) succinate (TPGS) (Figure 3) [40]. The study showed
that after micellar formulation, the gemcitabine conjugated onto the TPGS exhibited a reduction in
degradation (only 10% after 30 min) compared with free drug (89% after 30 min) due to cytidine
deaminase. In vitro cytotoxicity studies showed a 1.5-fold reduction in cytotoxicity against human
pancreatic adenocarcinoma (BxPC-3) cells. Gemcitabine usually enters the cellular lipid bilayer
using nucleoside transporters. Hence, reduction in the availability of transporters or deficiency
of their presence is one mechanism in which drug resistance may occur. Khare’s study showed
that the polymer-drug conjugate was capable of enhancement in cytotoxicity when compared to
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free gemcitabine when inhibition of the nucleoside transporters had occurred. Hence, the authors
concluded that the TPGS-gemcitabine polymer-drug conjugate held promise as a possible alternative
strategy for gemcitabine delivery moving forward [40].Pharmaceuticals 2017, 9, 39  6 of 25 
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Recently, Joubert et al. fabricated a gemcitabine polymer-drug conjugate for prolonged cytotoxicity
against PC [41]. The system developed was based on a methacrylate reversible addition-fragmentation
polymerization (RAFT), which would control the release rate of gemcitabine upon hydrolysis of
the ester and the amide link over long time periods. The study showed that release rate was
significantly increased when the pH decreased from pH 7 (20% after 30 days) to pH 5 (50% after
30 days). The polymer-drug conjugate exhibited a higher IC50 value in Mia PaCa-2 cells compared
with the free gemcitabine, however, the study was measured over 72 h and most likely the gemcitabine
had not been released from the polymer structure after this short duration, as observed in the release
studies. Hence, the cell viability was measured over 30 days. Interestingly, after 24 days the free
gemcitabine had completely lost all cytotoxic effect on the cells with 100% viability being observed.
However, in the cells treated with the polymer-drug conjugate, the cytotoxicity was maintained over
the 30-day period. These findings show the use of nanotechnology in formulating sustained release
systems which may prove more valuable compared to the current treatments due to their ability to
maintain an effect over long time periods [41].
Mittal et al. developed a polymer-drug conjugate composed of gemcitabine conjugated onto
a cationic poly(ethylene glycol)-block-poly(2-methyl-2-carboxyl-propylenecarbonate)-graft-dodecanol-
graft-cationic ligand [42]. The system was used not only to deliver the anticancer agent but also
to complex with a tumour suppressor miRNA-205 mimic. The system fabricated consisted of
a gemcitabine >10% which was capable of 4/1 polymer/miRNA-405 mimic complexation rate.
The system was tested in Mia PaCa-2 and CAPAN-1 cell lines in vitro and showed that the formulation
effectively reversed chemo-resistance, invasion and migration of the cells compared to free gemcitabine.
In vivo, a significant tumour growth inhibition was shown in Mia PaCa-2 xenografts with tumour
weight after study end reducing from 0.53 g (free gemcitabine) to 0.14 g with the polymer-drug
conjugate containing the miRNA-205 [42].
Another type of polymer, which fits into this class and had exhibited good potential as
a cancer therapeutic, is polymer-enzyme conjugates. Provenzano et al. reported the use of
a poly(ethylene glycol) linked with human recombinant PH20 hyaluronidase (PEGPH20) [79]. PH20 is
an enzymatic agent which targets the hyaluronic acid in the desmoplastic stroma in PC tumours.
Systemic administration of PEGPH20 in amurine PC xenograft resulted in a large decrease in tumour
stroma as well as a decrease in interstitial tumour pressure with an increase in the lumen diameter of
the blood vessels in the tumour [79]. PEGPH20 moved into Phase II clinical trial, however this was
halted when concerns over the observation of thromboembolic events in some patients. To circumvent
this heparin is now administered with the therapy. PEGPH20 is currently undergoing Phase III trial
given in combination with gemcitabine-nab-paclitaxel in a biomarker selected patient population with
HA-high levels [80].
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4.2. Amphiphilic Polymers
Amphiphilic polymers contain both hydrophobic and hydrophilic moieties, which spontaneously
aggregate into core-shell structures in aqueous environments [81]. This phenomenon is exploited
in drug delivery for the solubilisation of lipophilic compounds inside the hydrophobic core of the
aggregate formed. Amphiphilic polymers can exist in many different architectures dependant on
their molecular formation. These include block copolymers, graft polymers and dendrimers. Of all
the nanotechnologies described in this review, amphiphilic polymers represent the largest class of
technology which has been investigated for PC therapy.
4.2.1. Block Copolymers
Among the amphiphilic polymers, the most common type is block copolymers. Block copolymers
are fabricated from the polymerization of two or more types of monomer units in a linear fashion
(Figure 4A) [82]. Typically, one hydrophobic and one hydrophilic moiety becomes polymerised
resulting in an amphiphilic diblock copolymer e.g., poly(ethylene oxide)-block-poly(lactic acid)
(PEO-b-PLA) [83]. However, triblocks, tetrablocks, pentablocks etc., may also exist depending on
the monomer ratio. In aqueous solutions, block copolymers form aggregates spontaneously to form
polymeric micelles.
Characteristics of the micelles formed depend on the hydrophobic and hydrophilic monomer
blocks. Ethylene glycol is the most commonly used hydrophilic monomer. In its polymeric form
poly(ethylene glycol) is highly hydrated [84], an efficient steric protector [85], biocompatible [86]
and it has also been shown to prolong circulation times in blood [87]. The most commonly used
polymers for hydrophobic core formation are poly(esters) and poly(amino acids) [88,89]. The stability
of polymeric micelles depends on the type and molecular weight of the hydrophobic block. Generally,
the more hydrophobic and the higher the molecular weight, the greater the stability. In PC therapy,
block copolymers have shown to solubilise a plethora of potent anticancer agents for disease
treatment [43–45,90,91].
Kesharwani et al. reported the development of a styrene-maleic acid copolymer for the
solubilisation and delivery of 3,4-difluorobenzylidene curcumin (CDF) [43]. CDF is a non-toxic
analogue of curcimin, which in previous studies has shown to exhibit increased circulation times
and specific accumulation in the pancreas [92–94]. Tailoring of the block copolymer was undertaken
in order to achieve CDR loading of 5% to 15%. The polymer itself was found to release drug in
a sustained manner over a period between 100–120 h dependant on pH. The novel formulation was
tested on Mia PaCa-2 and AsPC-1 cell lines showing IC50 values relatively better than for the drug
alone. The high level of cellular internalisation of the formulation meant that it produced a promising
cytotoxic response, and further is being made to push this technology further into in vivo trials [43].
Recently, Veeren et al. reported the use of mixed micelles incorporating various anticancer
agents (gemcitabine, doxorubicin, doxorubicin hydrochloride, 5-fluorouricil and paclitaxel) for PC
therapy [45]. The mixed system was formed of poly(vinyl pyrrolidone-b-polycaprolactone) (PVP-b-
PCL) and poly(vinyl pyrrolidone-b-poly(dioxanone-co-methyl dioxanone)) (PVP-b-P(DX-co-MeDX).
As expected the more hydrophobic drugs encapsulated into the hydrophobic core of the micelles with
greater efficiency than the less hydrophobic ones. Conversely, the more hydrophilic the drug molecule,
the more rapidly release occurred into the aqueous surroundings. The toxicity of the nano-micelles
was tested on BxPC-3 and Panc-1 cells: here, the data suggested that the empty carriers themselves
were not toxic and hence any increase in toxic effect exhibited after formulation of the anticancer
agents was solely down to greater internalisation. In vitro studies showed that the formulation of
both gemcitabine and doxorubicin hydrochloride into one set of mixed micelles exhibited a greater
extent of toxicity compared to the exposure of the mixed free drugs or the two drugs incorporated
independently into micelles and exposed to the cell lines. These findings were independent of cell line
or micelle type. Hence, more work is being carried out in order to determine the cause of the synergy
and further potential of the system in vivo [45].
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Other studies have shown the use of block copolymer micelles with specific functionalities.
Ahn et al. reported the use of poly(ethylene glycol)-b-poly(glutamic acid) micelles for complexation
of metal based oxaliplatin anticancer agent [44]. After loading the surface of the micelles they were
conjugated with antibody fragments (Fab’). The study aimed to improve the efficacy of the Fab’ as
a drug tumour targeting agent. After BxPC-3 cell exposure to the formulation, the data showed that
the antibody conjugated-drug loaded micelles resulted in a 15-fold increase in cellular binding and
more rapid internalisation compared to the non-antibody conjugated formulation. The formulation
was tested in BxPC-3 xenografts, here a significant tumour inhibition was observed over 40 days
which resulted in a significant improvement compared to both the free drug and the unconjugated
counterpart [44]. These findings highlight how block copolymers can be used in order to promote
long-term tumour retardation compared to existing therapies.
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4.2.2. Graft Polymers
Graft polymers or comb shaped polymers are branched polymers comprising of a hydrophilic
homopolymer backbone with one or more hydrophobic pendant groups attached (Figure 4B) [95].
Like block copolymers, in aqueous environments these amphiphiles spontaneously aggregate into
self-assemblies due to a reduction in Gibbs free energy. Commonly graft polymers are formed from
cationic polymers with high molecular weights such as poly(ethylenimine) [96], poly(allylamine) [97]
and chitosan [98] etc. Due to their relatively recent development, not many reports on the use of graft
polymers for PC therapy have been reported.
Hoskins et al. developed a graft amphiphilic poly(allylamine) derivative capable of solubilising
hydrophobic drugs [46]. The polymer consisted of cholesteryl groups grafted in a 5% molar
ratio onto the cationic polymer backbone forming (poly(allylamine)-g-cholesterol) (Figure 5A).
The novel nano-carrier was used to solubilise a novel bisnaphthalimide based drug: Bisnaphthalimido
propyldiaamino octane (BNIPDaoct) (Figure 5B). BNIPDaoct had shown promise in vitro against
BxPC-3 cells, however, due to its inability to dissolve in aqueous formulations its progress was limited.
The study showed that BNIPDaoct was capable of incorporation into the hydrophobic core of the
micelle up to 0.3 mg·mL−1 at 1 mg·mL−1 polymer concentration and 1:1 polymer:drug loading ratio.
The formulation was administered in vivo on a BxPC-3 xenograft in nude tumour bearing mice over
a period of 4 weeks. Although the BNIPDaoct dose was eight-fold less than clinically used gemcitabine,
the formulation was able to reduce tumour growth in xenograft mice with comparable results [46].
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Bao et al. developed a chitosan grafted with poly(ethyleneimine) arms and candesartan conjugate
(CPC) for targeted delivery to PC cells [99]. The candesartan (CD) was capable of specific binding
onto angiotensin II type 1 receptors, which are over expressed in PC cells. The self-assemblies were
complexed with w-p53 genes. When exposed to Panc-1 cells there was a preferential uptake into cells
and a synergistic angiogenesis suppression was observed. The data showed that in Panc-1 xenografts
the CPC/wt-p53 formulation significantly inhibited tumour associated angiogenesis. This harmonised
system of halting tumour growth and decreasing tumour size may contribute to better success in the
development of targeted tumour treatment [99].
4.2.3. Dendrimers
Dendrimers are a category of repetitive, highly branched and thoroughly symmetrical polymers
(Figure 4C). The number of repeating branch points as traced from the dendrimer centre to the
periphery is called the generation. Dendrimer branches can act as selective gates to control the entry
of small molecules [100]. Terminal groups on the dendrimer boundary can be adjusted to manage
the solubility [101] and used as anchor points to enable functionalization with drugs, antibodies and
polymers [102,103].
Amphiphilic dendrimers form unimolecular micelles when in aqueous environments. The mechanism
of aggregation is dependent on the molecular makeup of the system but could involve hydrophobic or
electrostatic interactions or hydrogen bonding [104]. The hydrophobic core of a dendrimer is capable
of the encapsulation of hydrophobic drugs with controlled release profiles [105]. Entrapment can also
be achieved within the multivalent branching network and/or via adsorption onto the outer shell [106].
When a drug is covalently attached to the outer shell of a dendrimer, it will exhibit a decreased
release rate (if any—dependant on the binding mechanism) when compared to drug encapsulation
by hydrophobic or electrostatic interactions [107]. Dendrimers with high drug conjugation have been
shown to swiftly enter the cell and co-localise in the nucleus [107]. Of all the polymer nanotechnologies,
dendrimers are by far the smallest, with average sizes ranging from 2–20 nm dependant on structure.
Often with nanotechnologies, increase in drug efficacy can be attributed to increased (a) rate
of or (b) amount of drug internalisation into cells, which is likely to be influenced by uptake
mechanism. It is widely reported that endocytosis is the main route of nanotechnology internalisation.
However, this can be dependent on multiple factors including particle size, morphology, surface charge
etc. As such, studies have been conducted into the transfer of third generation poly(amidoamine)
(PAMAM) dendrimers labelled with Alexa Fluor 555 dye into Capan-1 cells visualised using confocal
microscopy [108]. Poitz et al. reported that after microscopy analysis the data was input to a simple
mass transfer model, which showed that the dendrimer was found to partition preferentially into the
cells with a mass transfer coefficient of 0.054 µm/min. This finding was comparable with other studies
where endocytosis was the uptake mechanism [108].
PC is one of the toughest cancers to treat due to its dense stroma hindering drug penetration.
Any method to improvement the uptake of drug into tumour cells may offer beneficial outcomes.
Kesharwani et al. as a follow-on study to the CDF loaded nanomicelles mentioned earlier in this
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review, have shown that PAMAM dendrimers with hyaluronic acid conjugation were capable of drug
solubilisation and targeted delivery of CDF [47]. PC cells are known to overexpress CD44 (an integral
membrane glycoprotein) on their surfaces [109,110]. As mentioned previously, CDF is a derivative
of curcumin with 16-fold longer half-life. As such, formulation into a dendrimer would render the
drug analogue soluble and would allow for clinical translation. Kesharwani reportedly achieved up to
17% entrapment efficiency of drug. Hyaluronic acid is capable of recognising and binding onto the
CD44 glycoproteins and hence exploitation of active transport may result in more effective therapies.
When the formulation was exposed to Mia PaCa-2 and AsPC-1 cell lines, a dose responsive toxicity
was observed. In order to determine whether the hyaluronic acid was effective as a targeting agent,
the CD44 in Mia PaCa-2 cells were blocked (saturated) by pre-treatment. The data showed that when
the glycoproteins were blocked, a 1.71-fold increase in IC50 was observed compared to the untargeted
formulation. This finding suggests that hyaluronic acid was indeed effective as an active targeting
agent for PC treatments [47].
Other studies have highlighted the potential of Flt-1 as a target for site-specific delivery to PC
tumour cells [48]. Flt-1 is a vascular endothelial growth factor (VEGF) receptor: these growth factors
are secreted in order to induce capillary growth, thus providing the tumour with a vasculature blood
supply. Hence, inhibition of this receptor would have a downstream effect and may result in more
positive treatment regimes. Ozturk et al. reported the use of poly(ethylene glycol) cored PAMAM
dendrimers with poly(ethylene glycol) surface modification. Additionally, anti-human Flt-1 was
conjugated onto the dendrimer surface. The dendrimer system was used as an inclusion complex for
incorporation of gemcitabine hydrochloride. The study showed that the gemcitabine was successfully
incorporated into the structure with a loading efficiency of 5. The release profile showed a steady
release over 20 h. When exposed to CFPAC-1 cells, the novel formulation experienced enhanced
cytotoxicity compared to the free drug. Additionally, in xenograft studies increased accumulation
was observed in tumour tissue. The authors concluded that this system may hold potential for
those patients who do not respond well to conventional chemotherapies due to its highly targetable
nature [48].
4.2.4. Smart Polymers
Over the past two decades polymer science has gone from strength to strength. As scientists
constantly strive to achieve more control over the site and or rate of delivery of therapeutics in order to
increase efficacy and reduce patient side effects [111–114]. Stimuli responsive or ‘smart polymers’ have
emerged as new front runners in the race for the ideal delivery system. Stimuli responsive polymers
undergo active responses (conformational change) to environmental change or external signals.
This makes them ideal as candidates for the active targeting of pharmaceuticals [114,115]. The reported
stimuli may either be physical (temperature, ultrasound, light), chemical (pH, ionic strength) or
biological (biomolecules) [114,116–118]. The major application reported for such technology is in the
delivery of anticancer therapeutics where precision control and site specificity is the ultimate desire.
Temperature responsive polymeric micelles are the most extensively studied to date [119–121].
Cancerous tissues possess an increased metabolic rate compared to normal healthy tissues [122] and
hence they exist at higher temperatures of 40–44 ◦C [122]. This highly localised temperature increase
renders thermo-responsive polymers a promising choice of drug carrier. Once the nano-carrier has
become internalised within the cell, the local temperature will increase which will result in polymeric
micelle deformation and hence drug release will occur.
Recently, Emamzadeh et al. presented the development of thermo-responsive copolymers
with a hydrophilic thermo-responsive block and a hydrophobic block [49]. The polymers formed
exhibit a thermo-reversible phase transition above 37 ◦C triggered by an external temperature
stimulus (such as ultrasound) resulting in micellar disruption and drug release. The polymers were
composed of poly[(di(ethylene glycol) methyl ether methacrylate-co-poly(ethylene glycol) methyl
ether methacrylate 300)-b-poly(2-ethylhexyl methacrylate)] [poly(diEGMAco-OEGMA300)-b-PEHMA].
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The self-assemblies formed in aqueous environments were capable of incorporating amino-protected
gemcitabine derivative, squalenoyl-Gemcitabine (sq-Gem) and PTX into their hydrophobic core.
The self-assemblies developed exhibited conformation change at 40 ◦C. In vitro cytotoxicity assays
carried out in Mia PaCa-2 cells, showed that combination therapy of the two cytotoxic drugs within
the self-assemblies exhibited a synergistic effect with considerably decreased cancer cell viability.
This study shows the great potential of thermo-responsive polymers in PC treatment [49].
pH responsive micelles can also be exploited as carriers in cancer treatment. The external pH
of tumour tissue has been reported to be around pH 6.75 as compared to pH 7.4 for normal healthy
tissue cells [115,116]. Additionally, the uptake mechanism of nanoparticles is largely reported to be
predominantly through the endocytic pathways. Once inside an endosome, the pH drops from pH 7.4
to approximately pH 4–6 [123]. Hence, tailoring the pH at which polymer breakdown or deformation
occurs can result in a highly site specific controllable release profile.
Li et al. developed an amphiphilic polymer from poly(styrene-alt-maleic anhydride) conjugated
through 2,4-diaminobutyric acid linkers with additional folic acid surface modification for targeting of
the folate receptor proteins up-regulated in PC cells [50]. The self-assemblies formed were capable of
forming in neutral pH, under which condition drugs could be incorporated into their hydrophobic core.
Upon reduction in pH, the polymer was unstable and collapsed resulting in drug release. In this study,
curcumin was used as a drug mimicking molecule due to its high level of lipophilicity. Once exposed
to Panc-1 cell lines, fluorescent microscopy confirmed that significant levels of curcumin had been
internalised compared to those aggregates without folic acid tags. Interestingly, the self-assemblies
appeared to exhibit rod-like association specific to the cells. The authors concluded that the system
developed possessed excellent potential as a site-specific pH responsive delivery system for PC
therapy [50].
Other studies have shown preferential drug release after micellar exposure to high frequency
ultrasound. Rapaport et al. developed paclitaxel-loaded Perfluorocarbon (PFC) nanodroplets in
combination with a PEO-co-PLA block copolymer, which they used with focussed ultrasound treatment
for PC treatment [124]. The time period between drug administration and application of the magnetic
resonance imaging guidance focussed ultrasound (MRgFUS) was proposed to have a remarkable
function in positive PC therapy. This was because the formulation required time to collect at the tumour
area to allow a suitable drug concentration to be present for release before MRgFUS application. By not
considering the time factor this would have caused damage to healthy tissue [124].
In another study, Rapaport et al. also synthesised a novel-intravenous paclitaxel loaded
nano-emulsion [51]. This nano-emulsion provided chemotherapy for PC via a conversion method
system from nano-emulsion to microbubbles through application of ultrasonic energy (90 KHz–1 MHz).
The tumour size decreased by the ultrasound activated system whereas the nano-emulsion not carrying
the paclitaxel had no effect on the tumour size. This demonstrated that the outcome was due to
the ultrasound-activated chemotherapeutic activity of the targeted paclitaxel and not solely on the
mechanical or thermal effect of the ultrasound [51].
4.3. Albumin
Albumin is the most abundant plasma protein used in the body for the transport of nutrients; this
is facilitated by its multiple binding sites and long circulatory half-life of approximately 19 days [125].
Albumin is well known as an effective drug carrier for lipophilic molecules [126] and has shown the
greatest success in PC treatment to date. Nanoparticle-albumin bound paclitaxel (Abraxane®) was
approved by the FDA in 2013 for treatment of metastatic PC. Abraxane® has demonstrated anticancer
action in preclinical studies as a single agent and cooperative activity jointly with gemcitabine in
murine PC models [52,53]. When administered in combination with gemcitabine, Abraxane® was
found to enhance the intra-tumoural concentration of gemcitabine [52,53].
Another international, large-scale, Phase III study demonstrated that Abraxane® in combination
with gemcitabine is a significantly better therapy than gemcitabine on its own [127]. The combined
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therapy showed noticeable improvement in survival in PC patients at all time points. Presence of
Abraxane® improved the cumulative delivery of gemcitabine. Longer treatment period and
higher cumulative dose in the Abraxane®/gemcitabine combination compared to gemcitabine alone
demonstrated that this formulation can be administered efficiently [127].
Kim et al. have constructed an albumin nanoparticle system for co-delivering curcumin and
paclitaxel (PTX), both of which possess significant anti-tumour activity for PC, through nanoparticle
bound albumin PTX/curcumin [128]. The particles were formed using high-pressure homogenisation.
The results of the study demonstrated that the formulation effectively released both drugs over a 24 h
period. Cellular internalised into Mia Paca-2 cells resulted in a 71% lower IC50 after exposure to the
combined treatment compared to particles only containing PTX. This technology showed the clinical
potential of an enhanced anticancer pharmaceutical agent to synergistically halt pancreatic tumours
and may lead to lower chemotherapy dosage in the future [128].
4.4. Inorganic Nanoparticles
Inorganic nanoparticles are arising as novel materials for biomedical applications due to their
distinct magnetic, electrical, optical and electrochemical properties [129] and their ability to possess
multifunctional properties [130]. The list of inorganic nanoparticles currently being fabricated with
biomedical application and hence potential as future PC therapies is growing rapidly. In this review,
we will cover the predominating particles showing potential in PC.
4.4.1. Carbon Nanotubes
Carbon nanotubes (CNTs) possess unique properties which can be harnessed for drug delivery
(Figure 6A). These include a good degree of biocompatibility [131] as well as their exceptional function
as drug conveyers with high target specificity and sensitivity [132]. CNTs have demonstrated to be
efficient transporters to the specific target regions for a wide range of molecules including drugs,
vaccines, proteins, small peptides, nucleic acids, vitamins and carbohydrates. The molecules are bound
either by attachment onto the outer surface or incorporated into the inner cavity of the tubes. CNTs with
surface functionalization have been shown to be more favourable in terms of biocompatibility and
ability to internalise into cells [133,134].
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Andreoli et al. reported the synthesis of a highly purified cationic CNT based on a single walled
tube coated with poly(ethylenimine) [135]. The study aimed to determine whether the cationic
CNTs were capable of entering the cells and assess their biocompatibility. In vitro studies in BxPC-3
cell lines showed that the CNTs coated with lower molecular weight poly(ethylenimine) resulted
in higher biocompatibility; this was confirmed in vivo in pancreatic xenografts, whereby the high
molecular weight PEI coated CNTs were found to cause local inflammation leading to necrosis
in vivo. Shorter CNTs with lower molecular weight PEI coatings were developed which did prove
biocompatible and showed colocation in both the cytoplasm and nucleus in PC cells [135]. This study
shows the importance of physical parameters when developing inorganic nanoparticles for medical
use, as they tend to carry a higher toxic burden than the synthetic polymers (though not in all cases).
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CNTs have been reported in the literature as photo-thermal heat sources after exposure to near
infrared irradiation [136]. Mocan et al. developed poly(ethylene glycol) coated multi-walled CNTs.
The CNTs were internalised into Panc-1 cells and subjected to irradiation at 808 nm. This irradiation
resulted in a heating effect which led to mitochondrial membrane depolarization. This membrane
depolarization activated the flux of free radicals within the cell, leading to cellular oxidative stress
and cell death. The authors concluded that the important findings may influence future combined
strategies with chemotherapies in order to produce more effective PC treatments [136].
Sophisticated CNT systems have also been developed which offer multifunctional properties.
Wang et al. recently reported the development of theranostic CNTs for image-guided phototherapy of
PC specifically in metastatic lymph nodes [137]. In this study, the multi-walled CNTs were filled with
MRI contrast agent gadolinium nanoparticles, which had been encapsulated within polydopamine.
The final construct was surface coated with poly(ethylene glycol). The CNTs were internalised into
BxPC-3 cells and irradiated with a 808 nm laser source, causing them to experience up to 32.4 ◦C in
heating. Mapping was achieved using MRI, but also visually it was obvious to the naked eye when
tissue had been stained black due to CNT accumulation. In vivo, the CNTs demonstrated lymphatic
mapping ability and photo-thermal ablation of both primary tumour sites as well as metastatic lymph
nodes [137]. Such an advanced technology could give hope to the millions of PC patients, where cancer
spread has occurred which dramatically reduces survival chances.
4.4.2. Quantum Dots
Quantum dots (QDs), are nano-sized semiconductor crystals, which possess unique optical and
electronic properties (Figure 6B) [138]. In particular, they exhibit bright and intensive fluorescence,
which is not easily quenched, unlike conventional fluorescent tags used in biomedicine [138]. QDs are
highly tunable and can offer near infrared (>650 nm) emission which is advantageous for tissue
imaging. Additionally, more than one QD can be combined in solution or tissue and each can be
excited using a single light wavelength and detected simultaneously for multiple assays. Hence, with
such potential a growing area of focus for QDs is for use as theranostics.
Yong et al. developed indium phosphate-zinc sulfide QDs for PC imaging [139]. The QDs were
prepared through hot colloid synthesis and coated with mercaptosuccinic acid for aqueous dispersion.
The surface of the QDs was functionalised using anti-Claudin4 in order to confer site-specific targeting.
Claudin 4 is known to be overexpressed in both primary and metastatic pancreatic tumours [140].
The QDs were incubated with Mia PaCa-2 and Panc-1 cells and viability determined over 48 h. Up to
100 mg·mL−1 the QDs were not shown to cause any significant decrease in viability over the study
duration. Cellular uptake was observed using confocal microscopy. Those cells treated with the
QDs showed excellent uptake with bright signals compared to their unlabelled (no anti-Claudin4)
counterparts [139]. The ease of synthesis and functionalisation and targetability of the QDs indicates
their potential as a diagnostic tool for PC.
Diagnosis of PC is often hindered by the lack of apparent biomarkers or indeed the
means to either detect or analyse these. As such Lee et al. have developed a QD approach
for quantitative molecular profiling of PC biomarkers [141]. The QDs developed consisted
of a CdS core with a (Cd,Zn)S shell. The surface of the QDs was functionalised with
1-myristoyl-2-hydroxy-sn-3-phosphocholine/1,2-dipalmitoyl-sn-glycero-3-phosphoethanol amine-N-
(lauroyl)-poly(ethylene glycol) to confer aqueous stability. Antibodies were conjugated onto the
surface in order to confer site specific targeting to the prostate stem cell antigen (PSCA), claudin-4 and
mesothelin (MSLN) biomarkers selected for the study. The QDs were exposed to a panel of PC cell lines
including Mia PaCa-2, Panc-1 and Capan-1. Upon exposure to cells the QDs exhibited highly selective
targeting with low levels of non-specific binding. The saturation of biomarkers on the cell surface was
confirmed and an absolute quantity of biomarker per mm2 could be deduced which was confirmed by
flow cytometry [141]. These findings are important as it offers a new approach for diagnosis of PC
using colour coded quantum dots.
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Other studies have been reported for the use of QDs for UV enhanced cytotoxicity. Here, CdTe QDs
were coated with mercaptopropionic acid and introduced into Panc-1 cells [142]. Once internalised
the QDs were exposed to UV radiation and the extent of cytotoxicity evaluated. The data showed
that metabolic activity of those cells containing QDs decreased upon UV irradiation in an exposure
duration dependant manner, while those cells treated to QDs and no irradiation experienced only slight
variation in metabolic activity. Further investigations showed that cells with QD plus UV irradiation
produced significantly increased levels of reactive oxygen species, which is known to be detrimental
to cell survival. Hence, this approach could be a simple and cost effective strategy in PC eradication
in vivo [142].
4.4.3. Iron Oxide Nanoparticles
Iron oxide nanoparticles (IONP’s) have applications in many medically related fields such as
cancer treatment, cancer detection, drug transportation, cell labelling and magnetic cell sorting
(Figure 6C) [143]. IONPs can exist in multiple shapes such as spherical, hexagonal, cubic and also
rods. IONP’s smaller than 20 nm are superparamagnetic which means that they gain magnetism
under a magnetic field. Unlike ferromagnetic materials, they do not retain their magnetism after the
magnetic field is removed [144,145]. Superparamagnetism only occurs with nanoparticles because
their size is small enough to occupy a single magnetic domain. This magnetic ability allows IONPs to
be useful as MRI contrast agents and can aid in cancer imaging and diagnosis. Superparamagnetic
IONPs can also attach drugs onto their surface as well as being magnetically guided to their target.
Once the field is removed the magnetism is lost and the IONPs will re-disperse in the surrounding
tissue, thus preventing aggregation and the likelihood of macrophage clearance [146].
Superparamagnetic IONPs have been developed by Arachchige et al. to enable MRI tracking and
to act as a drug carrier for doxorubicin [54]. Dextran coated IONPs were labelled with red fluorescing
doxorubicin as well as a green fluorescing fluorescein tag in order to track the in vitro fate of the
particles inside PC cells. The particles were incubated with Mia PaCa-2 cells. The results showed
that even in the absence of a targeting ligand, cellular internalization of doxorubicin had occurred
with a 20-fold increase compared with free drug. Additionally, the data showed that once inside the
cell doxorubicin was cleaved from the surface of the IONP allowing it to become localised within the
nucleus [54].
Recently, Trabulo et al. have developed an IONP with anticancer agent gemcitabine conjugated
onto its surface [55]. Additionally, in order to confer targeting ability anti-CD47, a monocloncal
antibody which inhibits the CD47 receptor (found on PC stem cells and not on normal pancreatic
cells), was also surface conjugated. The formulation was incubated with Panc-1, Panc 215 and Panc 354
cell lines. The data showed that, although there was no increase in overall cytotoxic effect using the
combined therapy compared to the free drug, the cellular uptake was improved and that both the
gemcitabine and CD47 retained their biological functions [55]. In 2D cell culture it is difficult to predict
in vivo fate and therefore this strategy may result in more site-specific delivery to patients and hence
less systemic drug circulation leading to unwanted side effects.
Magnetic IONPs will generate heat when subjected to strong magnetic fields. Magnetic crystal
suspensions of IONPs store the energy of alternating magnetic fields and release this energy as heat
causing hyperthermic stress in cancer cells [147]. Rochani et al. developed a sophisticated platform
based on IONP hyperthermia treatment of PC in conjunction with heat shock protein inhibition [148].
The IONPs used in this study, were coated with poly(lactic-co-glycolic acid). The surface was further
modified with 17-N-allylamino-17-dimethoxygeldanamycin (17AAG). 17AAG is a heat shock protein
inhibitor. Heat shock proteins are produced when cells are exposed to thermal increase, chemotherapy
or other stressful events. The production of these proteins is a coping mechanism of the cell in order to
avoid undue levels of stress and protect itself. The study showed that the coating concentration of
polymer effected not only the physicochemical properties, such a dispersion stability and particle size,
but also the magnetic ability of the particles which is required for hyperthermia. The findings suggested
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that the lower polymer concentration gave more favourable magnetic characteristics, perhaps due to
the higher concentration forming a thicker layer surrounding the iron oxide core. The dispersions
were incubated with Mia PaCa-2 cells and exhibited a time and dose dependant toxicity profile.
After cellular internalisation the particles were subjected to an alternating magnetic field, resulting in
localised heating of the nanoparticles and a reduction in cell viability of 75% compared to the control
cells [148]. This technology shows the potential as an alternative strategy to chemotherapy for future
clinical use.
Block copolymers based on poly(lactide-co-glycolide)-b-poly(ethylene glycol) incorporating iron
oxide nanoparticles with a matrix metalloproteinase-9 (MMP-9) cleavable linker have been developed
as an enzymatically activated platform [149]. MMP-9 is a protease which is upregulated in malignant
tumours. Protease cleavage of the Magh@PNPs-PEG-RegaCP-PEG construct formed resulted in
activation of the core components through removal of a poly(ethylene glycol) outer coating and
internalisation of smaller nanoparticles with their payload into the cancer cells. This was observed
using transmission electron microscopy from solution and light microscopy after internalisation into
9801 L pancreatic carcinoma cells. In vivo xenograft studies showed that the nanoparticle accumulated
in a tumour specific- and MMP-9 dependant manner. Grünwald et al. concluded that this system
holds good potential as a future therapeutic strategy for preferential targeting within PC tissue [149].
Another system developed exploiting similar mechanisms, is the cerium doped Fe3O4 with chitosan
coating based nanoparticles: CAN-Mag@PNPs-PEG-REGAcp-PPEG/tPApep1lac [150]. These particles
were developed to target the galectins Gal-1, Gal-3 and Gal-4. These galectins are known to be
overexpressed on the surface of PCs. The tPA-derived peptide incorporated into the structure was
used as a binding site for the nanoparticles while a proteolytically cleavable poly(ethylene glycol) shell
was used in order to prolong circulation and provide stealth properties before protease activation
from the monocyte phagocyctic system. The nanoparticles were tested in vivo in Panc-1 xenografts in
mice. The nanoparticles were well tolerated by the mice suggesting little associated toxicity. The study
demonstrated that the nano-construct was capable of higher levels of accumulation in the subcutaneous
tumours compared to the same nanoparticles without the outer shell. Additionally, magnetic resonance
imaging showed greater tumour uptake in the orthotropic model compared with the subcutaneous
tumour models, possibly due to the extent of vasculaturisation. The authors concluded that these
nano-carriers held potential as protease activated drug carriers and further work is underway in order
to fully exploit these systems for PC therapy [150].
4.4.4. Gold Nanoparticles
Gold nanoparticles (Figure 6D) have shown promise as useful carriers for targeted drug delivery.
Like IONP’s, gold nanoparticles also come in a variety of shapes, including spheres, rods and tetrapods.
Gold as an element is generally regarded as non-toxic. It is a noble metal that has filled d orbitals.
This makes gold resistant to oxidation, corrosion, and acidic conditions that can be found within the
body. Gold can be strongly covalently bonded to thiol groups, an organic functional group that can
be found on some drug compounds, or attached via the use of linkers [151]. Gold’s biocompatibility,
ability to carry drug formulations, ease of synthesis and surface plasmon resonance properties make it
a powerful tool in the treatment of PC. One characteristic of gold is its ability to absorb near infrared
(NIR) radiation and generate heat due to surface plasmon resonance (SPR). SPR is the term used to
describe the oscillation of free electrons when light is shone on a metal surface. These resonating
free electrons produce an electromagnetic wave (light) that travels away from the bulk phase of the
solid [152,153]. Generating heat using NIR radiation via SPR is ideal considering the high transparency
of tissue at that wavelength. A laser emitting NIR radiation can be used to target a specific area where
gold nanoparticles are situated, such as within a cluster of neoplasia in the pancreas. Heat generated
from the photo-thermal effect will raise the temperature of the cancer cells thus killing them due to
hyperthermia. Because the area of effect of heating using the laser is small, this also prevents damage
being caused to nearby healthy tissues [154].
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Mocan et al. showed that gold nanoparticles which undergo laser irradiation at 808 nm were
capable of interfering with the mitochondrial electron transfer chain in PC cells [155]. This interference
occurred through interaction of the activated electrons on the gold nanoparticle surface after laser
irradiation with the electrons inside the mitochondrial membrane in PANC-1 cells. This phenomenon
results mitochondrial membrane depolarization leading to lysis. The study also showed that
internalisation and irradiation of gold nanoparticles led to the inactivation of the Bcl-2 anti-apoptotic
proteins resulting in a decrease in MTP and ultimately necrosis. The authors concluded that this
data may represent a major step forward in the development of mitochondria-targeted PC treatments
using laser-activated gold nanoparticles [155]. Saha et al. reported the use of gold nanoparticles for
reprogramming the tumour microenvironment and inhibiting tumour growth in PC models [156].
The study showed that the gold nanoparticles were capable of disrupting the communication between
both Panc-1, AsPC-1 cell lines as well as fibroblast cells associated with PC (CAF19 and iTAF).
This communication breakdown was a result of alteration of the cell secretome. In the CAF19 and
iTAF, the gold nanoparticles were capable of reducing matrix deposition and hence inhibit tumour
growth in vivo in orthotropic PC models [156].
4.4.5. Hybrid Iron Oxide-Gold Nanoparticles
Hybrid nanoparticles are composed of an iron oxide core surrounded by a gold shell (Figure 6E).
The use of hybrid nanoparticles in nanomedicine has been reported over the past 5–10 years.
The nanoparticles themselves possess physical characteristics of both the iron oxide core (magnetism)
and the gold shell (biocompatibility and ability to act as a nano-heater). Hence, these multifunctional
platforms have proven useful in PC treatment.
Guo et al. reported the use of hybrid nanoparticles (GoldMag) as thermal ablation sites in for
PC therapy [157]. The GoldMag itself did display a degree of cytotoxicity with 47% cell viability
observed after 24 h incubation. The particles were internalised into Panc-1 cells and irradiated at
808 nm for 5 min. Thermal rise was observed up to 79.51 ◦C at 50 µg·mL−1. Photo-thermal ablation at
the same concentration resulted in reduction of the cell viability with only 2.3% live cells remaining.
Hence, the cytotoxic properties of the hybrid nanoparticles coupled with heat generation produced
a significant decrease in PC cell proliferation [157].
Another study that evaluated the potential of poly(ethylene glycol) coated hybrid iron
nanoparticles as heat triggers for PC therapy looked at both the in vitro and in vivo outcome of
administered hybrid nanoparticles and production of heat shock proteins (HSP-27 and HSP-70) which
are produced under heat-related stressful conditions in cells [158]. These proteins are classed as
molecular chaperones that assist various protein folding processes such as the folding of newly
synthesised proteins and the refolding of misfolded proteins [159]. In this study, the hybrid
nanoparticles were internalised into BxPC-3 cells and irradiated at 1064 nm for 60 s (or multiples
thereof). The data showed that the particles were capable of thermal increase of up to 9 ◦C with
heat dissipation over a total area of 346 mm2. Significant elevation in levels of the HSPs after laser
irradiation (50 µg·mL−1 HNP) indicate that the cells are stressed by the increase in the heat generated
by surface plasmon resonance of the gold surface. The effect of this heating on cell viability was
also determined, the results from this study were in line with those from the ELISA measurement of
heat shock proteins. At 50 µg·mL−1 HNP, cell viability fell to 85% after multiple laser irradiations.
Upon intra-tumoral injection in pancreatic xenograft models, a similar heating capacity was observed
at identical concentration which also resulted in bulk tumour dissipation [158].
Recently, Malekigorji et al. reported the use of hybrid nanoparticles as thermally triggered delivery
systems for novel bisnaphthalimide based chemotherapeutics [56]. The novel drugs were attached
onto the surface of the hybrid nanoparticles and the threshold temperature for release determined.
The findings showed that, bisnaphtalimido propyl spermine tetrahydrobromide (BNIPSpm) was
capable of binding onto the nanoparticle surface 3:1:0.25 drug:Fe:Au. At 44 ◦C, reversal of drug binding
occurred. The novel formulation was tested on BxPC-3 cells in vitro and showed a 12-fold reduction
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in IC50 after 24 h. In vivo a 5-fold increase in tumour retardation was experienced after irradiation
of the pancreatic xenografts in nude mice [56]. In another study, Oluwasanmi et al. developed
a system whereby gemcitabine is coupled covalently onto a hybrid gold-iron oxide nanoparticle
through a thermally labile linker, which undergoes a retro Diels Alder reaction, in order to improve
drug efficacy and specificity (Figure 7) [57]. Drug binding onto the hybrid surface through linker
attachment was achievable through dative covalent binding of a thiol in the linker onto the gold surface
of the nanoparticle. Upon heating (via laser irradiation, 1064 nm, 20 s) it was shown that rapid drug
release occurs which resulted in 62% reduction in tumour size when the formulation was introduced
intra-tumorally into a pancreatic xenograft model in nude mice. The exciting data highlights the ability
of the HNP-formulation to improve the cytotoxicity against PC adenocarcinoma compared with the
free drug and also promote tumour retardation more efficiently [57].Pharmaceuticals 2017, 9, 39  17 of 25 
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One common problem particularly affecting the use of inorganic nanoparticles for cancer
therapy is their higher relative toxicities [160] and accumulation within tissue [161] compared
to small molecules or biodegradable polymers. Commonly, reports have shown that inorganic
nanoparticles become trapped in the reticuloendothelial system and the liver [162]. This is usually due
to proteins adhering onto their surface forming a corona which largely increases their hydrodynamic
diameter [163]. In order to overcome this issue, studies have been carried out in order to coat these
inorganic particles with various stealth materials such as poly(ethylene glycol) [164]. which not only
can improve blood circulation times but also ability for renal clearance. Overcoming this issue is the
key hurdle for clinical translation of many of the inorganic nano-therapies under development.
5. Conclusions and Future Perspectives
As highlighted in this revie , the use of carefully for ulated nanotechnologies as drug carriers
or therapeutic agents has grown in traction for PC therapy. There is great promise in this field,
a s all number of nanotechnology formulations have made it through to the clinic for cancer therapy
and it is expected that many more will follow within the next 10–15 years. Currently Abraxane®
is the only nanotechnology (1–300 nm) which has made it through clinical trial and onto the
market for PC. Recently, in the UK, Abraxane® was not available to everyone through the National
Health Service, as the nano edicine was deemed too expensive. This decision has since been
overturned. However, this instance does need to be addressed when developing sophisticated
new technologies. If nanotechnology is to have a huge impact on this disease and on the lives
of its victims, the products hitting the market must be affordable. Indeed, there are also a lot of
unknowns surrounding nanotechnologies in medicine, such as where do the formulations end up,
how are they excreted, are they excreted, is there any long-term effects on accumulation or use
in hu ans. Only further research and time will tell. Ulti ately the goal for these studies is to
improve patient lives, any improvement in PC therapy is significant as the outlook is so bleak. It is
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our belief that nanotechnology and nanomedicines provide the solution to many problems faced
by current treatment strategies. These can be through earlier detection, increasing drug solubility,
prolonging circulation, improving penetration into solid tumours, drug targeting controlling release
duration and/or triggering release. The multifaceted approach to many of the systems under
development are overcoming these physiological barriers step by step, with the hope that, in time,
PC patients will face a brighter future upon diagnosis with improved quality of life and reduced
recurrence of cancer.
Author Contributions: Ayesha Manzur, Adeolu Oluwasanmi, Darren Moss, Anthony Curtis and Clare Hoskins
all contributed towards the writing and illustration of this manuscript.
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